GSK Licenses Chimagen Trispecific T-Cell Engager for Multiple Myeloma in Deal Worth Up to $750 Million
核心洞察
GSK has agreed to acquire full global rights to a trispecific T-cell engager from China-based Chimagen Biosciences (搜索) in a deal worth up to $750 million.
The experimental therapy is designed to bind T cells while simultaneously targeting two tumor-associated antigens, with Phase I testing expected to begin in 2027.
GSK plans to develop the asset for multiple myeloma (搜索), where it already markets Blenrep, approved by the FDA in a combination regimen in October 2025.
GSK has agreed to acquire full global rights to a trispecific T-cell engager from China-based Chimagen Biosciences (搜索) in a deal worth up to $750 million, adding a preclinical blood-cancer candidate to an oncology pipeline the company has been expanding through external business development.
The experimental therapy is designed to bind T cells while simultaneously targeting two tumor-associated antigens. GSK says the approach has the potential to produce deeper and more durable responses than existing T-cell engagers while improving tolerability. Those benefits remain potential rather than demonstrated clinical outcomes because the program has not yet entered human trials.
Development Plans in Multiple Myeloma
GSK plans to develop and commercialize the asset for multiple myeloma (搜索), an indication where it already markets Blenrep. The FDA approved Blenrep in a combination regimen in October 2025, allowing the blood-cancer drug to return to the U.S. market nearly three years after it had been withdrawn.
GSK expects the trispecific T-cell engager to begin Phase I testing in 2027. The company describes the asset as having the potential to offer differentiated efficacy and safety over existing T-cell engagers, and these are development goals based on the drug's design, not clinical results. Efficacy and tolerability in humans therefore remain to be evaluated.
Citing external commercial forecasts, GSK says the U.S. T-cell engager market for multiple myeloma (搜索) is expected to exceed $10 billion by 2032.
An Existing Chimagen Relationship
The transaction builds on a prior relationship with Chimagen. In 2024, GSK agreed to acquire CMG1A46, a dual CD19 (搜索)/CD20 (搜索) T-cell engager, for $300 million upfront and up to $550 million in additional development and commercial milestones. That program is already in Phase I development.
More broadly, the latest transaction follows GSK's $10.6 billion acquisition of lung-cancer specialist Nuvalent earlier this year, its largest acquisition in more than a decade.
A Separate HUTCHMED Licensing Deal
GSK has also moved to expand its oncology pipeline through a separate licensing agreement with HUTCHMED (China) Limited (搜索), announced September 3, covering HMPL-A830 (搜索) and targeting colorectal, pancreatic, and lung cancers. Under that agreement, HUTCHMED receives a $110 million upfront payment, potential milestone payments up to $1.3 billion, and tiered royalties on net sales, while granting GSK worldwide rights outside Greater China.
HUTCHMED will run the global Phase I clinical trials beginning in the second half of 2026, after which GSK assumes all operational and commercialization responsibilities across ex-China markets. The arrangement offloads ex-China late-stage development and commercialization costs to GSK while allowing HUTCHMED to lead Phase I trials through its integrated oncology platform.
For GSK, the HUTCHMED transaction fits into a targeted acquisition strategy that expands its oncology pipeline through external business development, alongside a stated target of achieving £40 billion in annual sales by 2031 and upcoming product launches including depemokimab and Blenrep. More than 50% of that 2031 sales target relies on existing on-market products, and spending capital on early-stage clinical candidates exposes the company to clinical development and eventual commercial execution risks.